WHO: Approved Vaccines “Respond” to All COVID-19 Variants So Far
Vaccines approved for use in the US and Europe show protection against all of the more infectious coronavirus variants known to be circling the globe.
Vaccines approved for use in the US and Europe show protection against all of the more infectious coronavirus variants known to be circling the globe.
The Spine Intervention Society sets out to separate myths from facts about the effect of corticosteroid injections on the efficacy of vaccines for COVID-19.
Although the vaccines efficacy lasts at least 6 months, fully vaccinated people will likely need a COVID-19 booster shot within about a year.
The risk for developing new clinical sequelae is increased after the acute phase of severe acute respiratory syndrome coronavirus 2.
The effectiveness of authorized mRNA COVID-19 vaccines against symptomatic COVID-19 is 82 and 94 percent for a single dose and for two doses.
Participants receiving heterologous prime and boost doses of COVID-19 vaccines have an increase in systemic reactogenicity after the boost.
After COVID-19 vaccination, recommendations are presented for the management of CVST with vaccine-induced immune thrombic thrombocytopenia.
The U.S. Centers for Disease Control and Prevention said Wednesday that COVID-19 vaccines can be given along with other childhood shots.
Existing patients receiving opioid analgesics and buprenorphine for opioid use disorder have continued to receive medications during the COVID-19 pandemic.
The unprecedented numbers of patients on mechanical ventilation underscore the severity of the coronavirus on public health. Elderly patients, especially those with Parkinson disease, often bear the brunt of the pandemic due to pre-existing pulmonary disease and/or anatomical disposition.